Heterometallic titanium–gold complexes inhibit renal cancer cells in vitro and in vivo

Fernández-Gallardo, Jacob; Elie, Benelita T.; Sadhukha, Tanmoy; Prabha, Swayam; Sanaú, Mercedes; Rotenberg, Susan A.; Ramos, Joe W.; Contel, Marı́a

doi:10.1039/c5sc01753j

Cited by 104 publications

(142 citation statements)

References 80 publications

Supporting

Mentioning

126

Contrasting

Unclassified

Order By: Relevance

“…27 Moreover, radiation-induced DNA damage is related to the inhibition of TrxR activity. 57 Here, the combined effects of Bi 2 Se 3 -CS-RGD NSs and X-ray irradiation on the TrxR activity in HeLa cells are studied. As shown in Figure 5a, the NSs and X-ray irradiation alone inhibit the TrxR activity slightly to 98.02% and 85.41%, respectively.…”

Section: Activation Of Ros-mediated Signaling Pathwaysmentioning

confidence: 99%

Decorated ultrathin bismuth selenide nanosheets as targeted theranostic agents for in vivo imaging guided cancer radiation therapy

et al. 2017

View full text Add to dashboard Cite

An efficient radiotherapeutic agent is synthesized using ultrathin two-dimensional 30-nm-wide and 2-nm-thick Bi 2 Se 3 nanosheets (NSs) as a radiosensitizer. Chitosan (CS) and RGD peptide are employed to enhance the radiotherapy efficiency and biocompatibility. The Bi 2 Se 3 -CS-RGD NSs exhibit excellent targeting ability to αvβ3 integrin-overexpressing cancer cells and potent radiosensitization efficiency with high stability. Detailed in vitro experiments show that the Bi 2 Se 3 -CS-RGD NSs enhance the sensitivity of HeLa cells to X-ray-induced cell death by inhibiting TrxR activities and activating downstream reactive oxygen species-mediated signaling pathways. In vivo experiments using intravenous or intratumor injection demonstrate that the Bi 2 Se 3 -CS-RGD NSs are more efficient tumor growth inhibitors compared to bare Bi 2 Se 3 NSs. The multifunctionality of the NSs enables the use of photoacoustic imaging and magnetic resonance imaging to examine their targeting ability and therapeutic effects, respectively. In addition, the RGD-decorated Bi 2 Se 3 NSs show much better in vivo biocompatibility and can be efficiently expelled from the body after 48 h post injection. This study reveals an effective and safe theranostic agent for next-generation cancer radiotherapy.

show abstract

Section: Activation Of Ros-mediated Signaling Pathwaysmentioning

confidence: 99%

Decorated ultrathin bismuth selenide nanosheets as targeted theranostic agents for in vivo imaging guided cancer radiation therapy

et al. 2017

View full text Add to dashboard Cite

show abstract

“…23–26 The hypothesis is that the incorporation of two active metals in the same molecule may improve their activity as anti-tumor agents due to interaction of the different metals with multiple biological targets (cooperative effect) or by the improved chemicophysical properties of the resulting heterometallic compound (synergism). We have prepared a number of titanocene-gold derivatives with high efficacy in ovarian and prostate cancer in vitro 23 and in renal cancer both in vitro 24 and in vivo 25 . We and others have also reported recently on the design of heterometallic ruthenium-gold complexes with relevant in vitro properties against HCT 116 colon cancer cell lines ( 7 and 8 in Chart 1).…”

mentioning

confidence: 99%

Versatile synthesis of cationic N-heterocyclic carbene–gold(i) complexes containing a second ancillary ligand. Design of heterobimetallic ruthenium–gold anticancer agents

et al. 2016

Self Cite

View full text Add to dashboard Cite

We describe a versatile and quick route to cationic gold(I) complexes containing N-heterocyclic carbenes and a second ancillary ligand (such as phosphanes, phosphites, arsines and amines) of interest for the synthesis of compounds with potential catalytic and medicinal applications. The general synthetic strategy has been applied to the preparation of novel cationic heterobimetallic ruthenium(II)-gold(I) complexes that are highly cytotoxic on renal cancer Caki-1 and colon cancer HCT 116 cell lines while showing a synergistic effect and being more selective than their monometallic counterparts.

show abstract

“…[65] The groups of Contel and Hey-Hawkins have synthesized gold/early-transition-metal complexes of the types 72 [66] and 73 [67] by reactiono fm etalloacids of the type H [69] ar emarkable anticancer activity,b eing ablet ob lock renal cancer growth both in vitro and in vivo. [66] Sordo and co-workers have studied the anticancer activity of di-or tetranuclearc omplexes 75 and 76,o btained by coordination of metalloligands of the type [74] À to LAg + or LAu + (L = PPh 3 )f ragments through both the carboxylate and thiolate groups (Figure 21). [68] ComplexH 4 [77]w as prepared by Konno and co-workers from racemic thiomalic acid and [Au 2 Cl 2 (dppe)] (Figure 22).…”

Section: Metalloligands Containing Pyridine Binding Sitesmentioning

confidence: 99%

The Coordination and Supramolecular Chemistry of Gold Metalloligands

Gil‐Rubio

Vicente

2017

Chemistry A European J

View full text Add to dashboard Cite

This review article deals with the use of gold metalloligands as building blocks for the assembly of heterometallic complexes.S everal families of gold complexes decorated with crown-ether, amide, pyridine, bipyridine, terpyridine, carboxylato, amino acid or p-alkyne binding sites have been reported. Adducts of these metalloligands with alkaline or transition-metal cations, or with transition-metal or lanthanide complexes, have been isolated ands tructurally characterized. The reported heterometallic species range from simple dinuclearc omplexes to self-assembled supramolecules, coordination polymers, or solids. New structuralm otifs have been found in thesec omplexes. Mosto ft hese metalloligandsa nd complexes are photoluminescent and some of them show switchable emissions based on the formation and rupture of metallophilic contacts. Potential applications as sensors, sensitizers, in vivo imaging agents, and anticancer drugs are envisaged.

show abstract

Heterometallic titanium–gold complexes inhibit renal cancer cells in vitro and in vivo

Abstract: Heterometallic compounds as anticancer agents demonstrating in vivo potential for the first time. Titanocene–gold derivatives: promising candidates for renal cancer.

Cited by 104 publications

References 80 publications

Decorated ultrathin bismuth selenide nanosheets as targeted theranostic agents for in vivo imaging guided cancer radiation therapy

Decorated ultrathin bismuth selenide nanosheets as targeted theranostic agents for in vivo imaging guided cancer radiation therapy

Versatile synthesis of cationic N-heterocyclic carbene–gold(i) complexes containing a second ancillary ligand. Design of heterobimetallic ruthenium–gold anticancer agents

The Coordination and Supramolecular Chemistry of Gold Metalloligands

Contact Info

Product

Resources

About